Howard Trachtman, MD

Aligning payer criteria with the FDA label, rather than the trial's narrower enrollment rules, may determine how many patients with this costly, progressive disease actually gain access to treatment.

The FDA label reaches further than the pivotal trial's inclusion criteria, and DUPLEX's own subgroup data reveals where the treatment effect holds strongest and where it does not.

A closely watched safety profile and a REMS program built for vigilance define how clinicians should approach monitoring patients starting on this dual receptor antagonist.

A missed primary endpoint obscured a proteinuria signal strong enough that regulators reconsidered what counts as meaningful evidence in FSGS, a recalibration with real implications for future trial design.

Behind sparsentan's approval sits a trial built on stringent inclusion criteria and evolving endpoint science, raising hard questions about which real-world FSGS patients the data actually represents.

As sparsentan enters practice, corticosteroids and RAS inhibitors retain a role for select patients, while clinicians weigh how and when to transition existing therapy toward the newly approved option.

A four-category classification and a growing list of implicated genes still leave real gaps in understanding FSGS, but sparsentan's approval marks the first therapy built specifically around its dual-injury mechanism.

FSGS is not a single disease but a shared pattern of podocyte injury that spans every age group, from pediatric to adult nephrology, demanding equal attention regardless of a patient's age or underlying cause.